Target pain relief from the earliest diagnosed stages of canine Osteoarthritis (OA)
Galliprant™ is a first-in-class prostaglandin receptor antagonist (PRA), a non-COX inhibiting NSAID. It specifically targets the EP4 receptor, the primary mediator of canine OA pain and inflammation1. You can start treatment from the earliest diagnosed stages. Give these dogs the relief they need and help keep them doing the things they love.
What is canine osteoarthritis?
Canine osteoarthritis is the most common cause of chronic pain in dogs2 and it doesn’t just occur in older, heavy dogs. It’s a painful disease that causes inflammation and swelling in a dog’s joints.
Early management and its benefits
Once pain sets in, a dog is less likely to move and may put on a few extra pounds. That can put more stress on joints and may lead to even more inflammation and pain. It’s a vicious cycle.
Features of Galliprant™
Mode of action targets canine OA pain and inflammation while reducing the impact on GI, kidney and liver homeostasis1,3.
Suitable for dogs as young as 9 months of age.
Most dogs can be dosed with a whole or half tablet.
Our Product
Galliprant™ 20mg
Galliprant™ 60mg
Don’t take our word for it. Take theirs
LOOKING FOR Galliprant™?
Download now to locate your nearest Vet
Indications
For the treatment of pain and inflammation associated with osteoarthritis in dogs.
Use as directed by prescribing veterinarian.
Important Safety Information
The safety of GALLIPRANT™ has not been established in dogs weighing less than 3.6 kg or in dogs less than 9 months of age. The use of GALLIPRANT™ in dogs with cardiac disease has not been studied. It is not known whether dogs with a history of hypersensitivity to sulfonamide drugs will exhibit hypersensitivity to GALLIPRANT™. Concomitant use of GALLIPRANT™ with corticosteroids or (other) anti-inflammatory drugs, such as COX-inhibiting NSAIDs, should be avoided. Patients with gastro-intestinal disease should be closely monitored during treatment. Drug compatibility should be monitored in patients requiring adjunctive therapy.
Please see product insert for full prescribing information.
DISCLAIMER
Galliprant™ is a trademark of Elanco or its affiliates.
PM-MY-22-0153
REFERENCE
- Shaw KK, Rausch-Derra L, Rhodes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2016; 2:3-9.
- Fox SM, Millis D. Osteoarthritis: The Disease. Multimodal Management of Canine Osteoarthritis. Boca Raton, FL: Manson Publishing Ltd; 2010:24.
- Rausch-Derra, LC et al. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. Am J Vet Res. 2015;76: 853-9.
